The licence allows manufacturers to develop and sell generic medicines containing bictegravir, if it is approved in the United States.
Gilead Sciences and the MPP are also expanding the geographical scope of licences on other HIV products, enabling generic medicines to be supplied to additional countries such as Belarus, the Philippines, Malaysia and Ukraine.
The new licences are aimed at providing low- and middle-income countries “improved, simplified treatment options, crucial for people living in resource-limited settings," said Greg Perry, executive director of the MPP.
Lelio Marmora, executive director of Unitaid, MPP's funder, said: “We're tremendously pleased with the MPP and Gilead's collaborative efforts over the many years to improve health outcomes in low- and middle-income countries.”
"Through their joint HIV licensing programme, millions stand to benefit from quality-assured generics of new optimised treatment regimens."
Gregg Alton, executive vice president for corporate and medical affairs at Gilead Sciences, added: “These agreements allow for our licensees to provide generic versions of our latest therapies to people living with HIV in the developing world.”
He added: “Today, more than 10 million people in resource-limited countries are on Gilead-based HIV therapies, which would not be possible without these strong alliances.”